| |
| | PRESS RELEASE Vela Pharmaceuticals Announces Completion Of Phase II Trial Of Very-Low Dosage Cyclobenzaprine In ... (Site not responding. Last check: 2007-10-12) |
 | | In this study, subjects received either very-low dosage cyclobenzaprine (1–4 mg, taken as a single dose before bedtime), or placebo for eight weeks. |
 | | Results indicate that, compared to placebo, very-low dosage cyclobenzaprine dramatically reduced musculoskeletal pain and fatigue, and improved sleep. |
 | | “Cyclobenzaprine, taken in much higher dosages, usually several times a day, has been widely used for the treatment of muscle spasm,” said Kevin L. Keim, MSc, PhD, President and CEO of VelaPharm. |
| www.marketwire.com /mw/release_html_b1?release_id=48015 (272 words) |
|